Loading data…
Nasus Pharma Ltd
3 transactions · Newest trade first
Accepted in the last 30 daysNo qualifying insider buying. No qualifying insider sales.
Filing activity uses public SEC acceptance timestamps. The qualifying-buys metric above uses trade dates at the snapshot cutoff.
$7,802 of common-equity purchase value after transaction-age decay across 180 days.
1 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Score is not a probability of profit or a recommendation to trade.
This reflects the filings imported so far, not a complete trading history.